Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

443TiP - A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)


22 Nov 2020


e-Poster Display Session


Cancer in Adolescents and Young Adults (AYA)

Tumour Site



Nathalie Gaspar


Annals of Oncology (2020) 31 (suppl_6): S1407-S1415. 10.1016/annonc/annonc368


N. Gaspar1, Q. Campbell-Hewson2, S.S. Bielack3, M. Campbell4, F. Bautista5, C. Meazza6, K. Janeway7, F.S. Dela Cruz8, S. Whittle9, D.A. Morgenstern10, L. Dutta11, J. McKenzie11, K. O'Hara12, J. Huang13, C.E. Okpara12, B. Bidadi14, K. Koh15, B. Moreland16

Author affiliations

  • 1 Department Of Childhood And Adolescent Oncology, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 2 The Great North Children's Hospital, Royal Victoria Infirmary, NE7 7DN - Newcastle Upon Tyne/GB
  • 3 Department Of Pediatric Oncology, Hematology, Immunology, Klinikum Stuttgart - Olgahospital, 70174 - Stuttgart/DE
  • 4 Children's Cancer Centre, Royal Children's Hospital Melbourne, 3052 - Melbourne/AU
  • 5 Pediatric Oncology Service, Hospital del Niño Jesús, 28009 - Madrid/ES
  • 6 Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milano/IT
  • 7 Department Of Pediatric Oncology, Dana-Farber Cancer Institute, 02115 - Boston/US
  • 8 Department Of Pediatrics, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 9 Department Of Pediatrics, Section Of Hematology-oncology, Texas Children's Cancer Center, Baylor College of Medicine, 77030 - Houston/US
  • 10 Division Of Pediatric Hematology/oncology, The Hospital for Sick Children, M5G 1X8 - Toronto/CA
  • 11 Clinical Research, Eisai Inc., 07677 - Woodcliff Lake/US
  • 12 Clinical Research, Eisai Ltd., AL10 9SN - Hatfield/GB
  • 13 Biostatistics, Eisai Inc., 07677 - Woodcliff Lake/US
  • 14 Clinical Research, Merck & Co. Inc., 07033 - Kenilworth/US
  • 15 Division Of Pediatric Hematology/oncology, Department Of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 16 Department Of Paediatric Oncology, Birmingham Women's and Children's Hospital, B4 6NH - Birmingham/GB


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 443TiP


Osteosarcoma is a bone malignancy that occurs primarily in adolescents and young adults. Approximately 30% of patients (pts) with localized disease and 80% of pts with metastatic disease at diagnosis will relapse. Lenvatinib (LEN) is a multikinase inhibitor that directly inhibits tumor growth, and may increase the uptake of chemotherapy into tumor tissue by inhibiting angiogenesis. In a phase I/II study (E7080-G000-207; ITCC-050), LEN (14 mg/m2 dose) + ifosfamide (I) + etoposide (E) demonstrated a PFS rate at 4 months (PFS-4m) of 80% (95% CI: 61–91), with a manageable safety profile in pts with relapsed/refractory osteosarcoma (Gaspar ESMO 2019). This study aims to confirm the activity of LEN + I and E that was observed in the completed phase I/II study.

Trial design

This study will evaluate LEN in combination with I and E in pts (proposed N=72, with randomization of at least 32 pts < 18 yrs old) aged 2 to 25 yrs with confirmed diagnosis of osteosarcoma that is refractory or relapsed following 1-2 prior systemic treatments. Pts previously treated with I and E are eligible, except those with a history of I-related grade ≥ 3 nephrotoxicity or encephalopathy. Randomization will be stratified by time to first relapse/refractory disease (< 18 or ≥ 18 mos) and by age (< 18 or ≥ 18 yrs). Pts in arm A will receive daily oral LEN 14 mg/m2 + I 3000 mg/m2/day (IV, Days 1-3 of each cycle for ≤5 cycles) and E 100 mg/m2/day (IV, Days 1-3 of each cycle for ≤5 cycles). Pts in arm B will receive I 3000 mg/m2/day (IV, Days 1-3 of each cycle for ≤5 cycles) and E 100 mg/m2/day (IV, Days 1-3 of each cycle for ≤5 cycles). Treatment will occur in 21-day cycles. The primary objective is PFS-4m by independent imaging review (IIR) using RECIST 1.1 (% of pts alive without progressive disease at week 18). Secondary objectives include PFS, OS, ORR, safety and tolerability, LEN pharmacokinetics characterization in pts in arm A, and quality of life. Tumor assessments will be performed by the investigator every 6 wks. Disease progression must be confirmed by IIR. All AEs will be recorded.

Clinical trial identification


Legal entity responsible for the study

Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.


Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.


N. Gaspar: Advisory/Consultancy, Travel/Accommodation/Expenses: Eisai; Advisory/Consultancy: Ipsen. Q. Campbell-Hewson: Travel/Accommodation/Expenses: Eisai. S.S. Bielack: Advisory/Consultancy, Research grant/Funding (institution): Bayer; Advisory/Consultancy: Lilly; Advisory/Consultancy: Sensorion; Advisory/Consultancy: Ipsen; Advisory/Consultancy: Roche; Advisory/Consultancy: Boehringer Ingelheim; Research grant/Funding (institution): Eisai; Research grant/Funding (institution): Loxo. F. Bautista: Honoraria (self), Advisory/Consultancy: Amgen; Honoraria (self), Travel/Accommodation/Expenses: Jazz Pharmaceuticals; Advisory/Consultancy: Bayer; Advisory/Consultancy, Travel/Accommodation/Expenses: EUSA Pharma; Travel/Accommodation/Expenses: Takeda. C. Meazza: Speaker Bureau/Expert testimony: Takeda. K. Janeway: Advisory/Consultancy, Travel/Accommodation/Expenses: Bayer; Research grant/Funding (institution): Amgen. D.A. Morgenstern: Advisory/Consultancy: Boehringer-Ingelheim; Advisory/Consultancy: Roche; Advisory/Consultancy: Bayer; Research grant/Funding (institution): Bristol-Myers Squibb; Travel/Accommodation/Expenses: EUSA Pharma. L. Dutta, J. McKenzie, K. O'Hara, J. Huang, C.E. Okpara: Full/Part-time employment: Eisai. B. Bidadi: Full/Part-time employment: Merck & Co. Inc.; Shareholder/Stockholder/Stock options: Merck. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.